Product Usage: This PRODUCT IS INTENDED AS A RESEARCH CHEMICAL ONLY. This designation allows the use of research chemicals strictly for in vitro testing and laboratory experimentation only. All product information available on this website is for educational purposes only. Bodily introduction of any kind into humans or animals is strictly forbidden by law. This product should only be handled by licensed, qualified professionals. This product is not a drug, food, or cosmetic and may not be misbranded, misused or mislabeled as a drug, food or cosmetic
Retatrutide
Retatrutide
$72.00 – $425.00Price range: $72.00 through $425.00
Retatrutide (LY3437943) is a synthetic 39-amino-acid triple-agonist peptide targeting GLP-1R, GIPR, and GCGR receptors, designed for controlled investigations of energy expenditure, glucose homeostasis, lipid metabolism, and obesity-related pathways.
Retatrutide is an investigational triple-hormone receptor agonist developed by Eli Lilly that simultaneously activates glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This unique tri-agonist profile produces synergistic effects on appetite suppression, insulin sensitivity, hepatic fat clearance, and thermogenesis — far exceeding dual-agonist (GLP-1/GIP) peptides like tirzepatide in preclinical and early human data. This research-grade lyophilized powder is synthesized under strict quality controls and provided with full analytical documentation, making it the gold-standard tool for next-generation metabolic, obesity, and diabetes research.
Key Scientific
- High-purity Retatrutide (≥ 98% by HPLC/MS, acetate salt form)
- Verified 39-amino-acid sequence with lipidation and proprietary modifications for extended half-life
- Lyophilized formulation for maximum long-term stability
- Full Certificate of Analysis (COA) with HPLC, MS, amino acid analysis, and receptor-binding data
- Manufactured in GMP-aligned, ISO-compliant facilities
- Ideal for triple-agonist, energy balance, and NAFLD/NASH research models
Research-Referenced Attributes (Based on published clinical and preclinical literature; not therapeutic claims.)
- Triple agonism (GLP-1 + GIP + Glucagon) → superior weight loss vs. dual-agonists
- Phase-2 human trials: up to −24.2% body weight reduction at 48 weeks (typical concentration is 12 mg dose) ic — the highest reported for any incretin-based therapy to date
- Dramatic HbA1c reduction (−2.02%) and normalization of liver fat (>70% resolution of MASH in biopsy sub-study)
- Significant elevation of energy expenditure and fat oxidation via glucagon receptor activation
- Marked triglyceride reduction (−42% to −60%) and improvements in cardiometabolic markers
- Dosing profile with favorable tolerability in clinical cohorts
- Valuable across obesity, type 2 diabetes, metabolic dysfunction-associated steatohepatitis (MASH), and cardiovascular outcome research
Why Researchers Choose Nationwide Peptides Retatrutide
- Exact clinical-grade sequence match to LY3437943 (including lipidation)
- Highest reported purity and receptor-binding fidelity among research suppliers
- Transparent analytical data (HPLC >98%, triple-receptor activity confirmed)
- Trusted by academic, pharmaceutical, and metabolic-disease laboratories worldwide
- Competitive research pricing with bulk options
Storage & Handling
- Store lyophilized powder at –4 °F (long-term) or 39.2 °F (short-term)
- Store in a tightly sealed container and protect from light, moisture, air exposure, and elevated temperatures.
- Reconstitute only with bacteriostatic water or sterile saline (typical concentration 5–10 mg/mL)
- Reconstituted solutions stable at 39.2 °F for up to 4 weeks; avoid repeated freeze-thaw cycles
- Use appropriate PPE and aseptic techniques
Peptide Research
- In a Phase 2 trial (n=338 obese adults), once-weekly retatrutide (4-12 mg) led to -17.5% body weight at 24 weeks and -24.2% at 48 weeks (vs. -2.0% placebo), with greater reductions in abdominal fat and lean mass preservation due to glucagon’s thermogenic effects. – https://pubmed.ncbi.nlm.nih.gov/37366315/ https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Reduced HbA1c by -2.02% at 48 weeks in obesity trials; a Phase 1b study (n=72 T2D patients) showed dose-dependent fasting glucose drops (-1.5 to -2.5 mmol/L) via enhanced insulin secretion and glucagon modulation. – https://pubmed.ncbi.nlm.nih.gov/38367045/
- Meta-analysis of Phase 2 data showed -42% to -60% triglyceride reduction, improved insulin sensitivity, and potential anti-cancer effects (e.g., 14-fold tumor volume reduction in preclinical pancreatic models via reduced obesity-driven inflammation) – https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/
- Jastreboff et al. (2023) Phase 2 obesity trial [PMID: 37366315, https://pubmed.ncbi.nlm.nih.gov/37366315/]
- Jastreboff et al. (2023) NEJM full publication [DOI: 10.1056/NEJMoa2301972, https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- Sattar et al. (2024) Phase 2a MASH trial [DOI: 10.1038/s41591-024-03018-2, https://www.nature.com/articles/s41591-024-03018-2].
- Hu et al. (2024) Meta-analysis [PMC: PMC12026077, https://pmc.ncbi.nlm.nih.gov/articles/PMC12026077/]
- ClinicalTrials.gov Phase 3 trials (e.g., NCT05882045, NCT05929066, ongoing as of 2025).
COA
